NewEdge Advisors’s Orchestra BioMed OBIO Stock Holding History

NewEdge Advisors’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$190K	Hold	44,083	–	–	﹤0.01%	2791
2026 Q1	$187K	Hold	44,083	–	–	﹤0.01%	2611
2025 Q4	$183K	Hold	44,083	–	–	﹤0.01%	2604
2025 Q3	$109K	Hold	44,083	–	–	﹤0.01%	2578
2025 Q2	$118K	Buy	+44,083	New	+$129K	﹤0.01%	2367

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

NewEdge Advisors's OBIO Position: Q2 2026 in Review

NewEdge Advisors held its Orchestra BioMed (OBIO) position steady in Q2 2026 at 44,083 shares worth $190K. The position accounts for ﹤0.01% of the portfolio, ranked #2791.

NewEdge Advisors first reported a position in OBIO in Q2 2025 and has held it in 5 quarters since. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

NewEdge Advisors held 44,083 shares of Orchestra BioMed worth $190K as of Q2 2026.
NewEdge Advisors left its Orchestra BioMed share count unchanged in Q2 2026.
Orchestra BioMed made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #2791 holding.
NewEdge Advisors first reported a position in Orchestra BioMed in Q2 2025 and has held it in 5 quarters since.
77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.